Literature DB >> 11974507

[Eccrine sweat gland carcinoma of the skin].

A Rütten.   

Abstract

Sweat gland carcinomas represent a group of morphological heterogeneous tumors with clear differences regarding clinical course and prognosis. The most relevant and accepted entities are described clinically and histopathologically with special reference to the differentiation from benign adnexal tumors. Carcinomas arising from preexisting benign adnexal tumors such as spiradenocarcinoma, cylindrocarcinoma, malignant mixed tumors of the skin are easily recognized. To establish the diagnosis of microcystic adnexal carcinoma or aggressive digital papillary adenocarcinoma can be more difficult, because these carcinomas do not show cytological criteria for malignancy and may therefore resemble benign adnexal tumors especially in small specimens.

Entities:  

Mesh:

Year:  2002        PMID: 11974507     DOI: 10.1007/s00292-001-0516-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  4 in total

1.  [Eccrine porocarcinoma of the head. Report 3 cases].

Authors:  P A Gerber; D Bruch-Gerharz; K W Schulte; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2005-04       Impact factor: 0.751

Review 2.  [Sweat gland carcinomas of the skin].

Authors:  A Rütten; L Requena
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

3.  Primary cutaneous adenoid cystic carcinoma of the scalp: A case report, immunohistochemistry and review of the literature.

Authors:  Bhakinai Temnithikul; Suthat Rungrunanghiranya; Piyakan Limtanyakul; Suthep Jerasuthat; David G Paige
Journal:  Skin Health Dis       Date:  2022-04-28

4.  Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.

Authors:  Regina C Betz; Silke Redler; Evgeniya Denisova; Dana Westphal; Harald M Surowy; Friedegund Meier; Barbara Hutter; Julia Reifenberger; Arno Rütten; Alexander Schulz; Mildred Sergon; Mirjana Ziemer; Benedikt Brors
Journal:  Cancer Gene Ther       Date:  2021-05-27       Impact factor: 5.854

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.